Literature DB >> 9745430

Familial hyperaldosteronism type II: description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene.

D J Torpy1, R D Gordon, J P Lin, P R Huggard, S E Taymans, M Stowasser, G P Chrousos, C A Stratakis.   

Abstract

Familial hyperaldosteronism type II (FH-II) is characterized by autosomal dominant inheritance and hypersecretion of aldosterone due to adrenocortical hyperplasia or an aldosterone-producing adenoma; unlike FH type I (FH-I), hyperaldosteronism in FH-II is not suppressible by dexamethasone. Of a total of 17 FH-II families with 44 affected members, we studied a large kindred with 7 affected members that was informative for linkage analysis. Family members were screened with the aldosterone/PRA ratio test; patients with aldosterone/PRA ratio greater than 25 underwent fludrocortisone/salt suppression testing for confirmation of autonomous aldosterone secretion. Postural testing, adrenal gland imaging, and adrenal venous sampling were also performed. Individuals affected by FH-II demonstrated lack of suppression of plasma A levels after 4 days of dexamethasone treatment (0.5 mg every 6 h). All patients had negative genetic testing for the defect associated with FH-I, the CYP11B1/CYP11B2 hybrid gene. Genetic linkage was then examined between FH-II and aldosterone synthase (the CYP11B2 gene) on chromosome 8q. A polyadenylase repeat within the 5'-region of the CYP11B2 gene and 9 other markers covering an approximately 80-centimorgan area on chromosome 8q21-8qtel were genotyped and analyzed for linkage. Two-point logarithm of odds scores were negative and ranged from -12.6 for the CYP11B2 polymorphic marker to -0.98 for the D8S527 marker at a recombination distance (theta) of 0. Multipoint logarithm of odds score analysis confirmed the exclusion of the chromosome 8q21-8qtel area as a region harboring the candidate gene for FH-II in this family. We conclude that FH-II shares autosomal dominant inheritance and hyperaldosteronism with FH-I, but, as demonstrated by the large kindred investigated in this report, it is clinically and genetically distinct. Linkage analysis demonstrated that the CYP11B2 gene is not responsible for FH-II in this family; furthermore, chromosome 8q21-8qtel most likely does not harbor the genetic defect in this kindred.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9745430     DOI: 10.1210/jcem.83.9.5086

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Primary aldosteronism: rare bird or common cause of secondary hypertension?

Authors:  M Stowasser
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  A novel point mutation in the KCNJ5 gene causing primary hyperaldosteronism and early-onset autosomal dominant hypertension.

Authors:  Evangelia Charmandari; Amalia Sertedaki; Tomoshige Kino; Christina Merakou; Dax A Hoffman; Michael M Hatch; Darrell E Hurt; Lin Lin; Paraskevi Xekouki; Constantine A Stratakis; George P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  2012-05-24       Impact factor: 5.958

Review 3.  Pathogenesis of Familial Hyperaldosteronism Type II: New Concepts Involving Anion Channels.

Authors:  Michael Stowasser; Martin Wolley; Aihua Wu; Richard D Gordon; Julia Schewe; Gabriel Stölting; Ute I Scholl
Journal:  Curr Hypertens Rep       Date:  2019-04-04       Impact factor: 5.369

Review 4.  Miscellaneous endocrine causes of hypertension.

Authors:  Richard J Auchus
Journal:  Curr Cardiol Rep       Date:  2005-11       Impact factor: 2.931

Review 5.  Hereditary causes of primary aldosteronism and other disorders of apparent excess mineralocorticoid activity.

Authors:  Xin He; Zubin Modi; Tobias Else
Journal:  Gland Surg       Date:  2020-02

6.  ARMC5 is not implicated in familial hyperaldosteronism type II (FH-II).

Authors:  S M C De Sousa; M Stowasser; J Feng; A W Schreiber; P Wang; C N Hahn; R D Gordon; D J Torpy; H S Scott; L Gagliardi
Journal:  J Hum Hypertens       Date:  2017-10-12       Impact factor: 3.012

7.  A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22).

Authors:  A R Lafferty; D J Torpy; M Stowasser; S E Taymans; J P Lin; P Huggard; R D Gordon; C A Stratakis
Journal:  J Med Genet       Date:  2000-11       Impact factor: 6.318

8.  Autoimmune mechanisms activating the angiotensin AT1 receptor in 'primary' aldosteronism.

Authors:  David C Kem; Hongliang Li; Carolina Velarde-Miranda; Campbell Liles; Megan Vanderlinde-Wood; Allison Galloway; Muneer Khan; Caitlin Zillner; Alexandria Benbrook; Veitla Rao; Celso E Gomez-Sanchez; Madeleine W Cunningham; Xichun Yu
Journal:  J Clin Endocrinol Metab       Date:  2014-02-19       Impact factor: 5.958

Review 9.  cAMP/PKA signaling defects in tumors: genetics and tissue-specific pluripotential cell-derived lesions in human and mouse.

Authors:  Constantine A Stratakis
Journal:  Mol Cell Endocrinol       Date:  2013-02-26       Impact factor: 4.102

Review 10.  Heritable forms of hypertension.

Authors:  V Matti Vehaskari
Journal:  Pediatr Nephrol       Date:  2007-07-24       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.